Table 2.
Response and prognosis after 4SCAR-GD2 T-cell therapy
| No. | Response at 6 months | Response at 1 year | Disease re-progression (months)a | Re-relapsed sites | Time of 4SCAR-GD2 T cell last detected (days after infusion) | Time to follow-up (years) | Long-term outcome |
|---|---|---|---|---|---|---|---|
| 1 | SD | PD | 11 | Bone marrow | 34 | 2 | DOD |
| 2 | SD | SD | – | – | 148 | 4 | SD |
| 3 | PD | PD | 3 | Cerebral metastasis | 114 | 4 | DOD |
| 4 | SD | SD | – | – | 57 | 4 | SD |
| 5 | PD | PD | 5 | Bone and soft tissue masses | 121 | 1 | DOD |
| 6 | SD | SD | – | – | 102 | 4 | SD |
| 7 | PD | PD | 8 | Bone marrow | 72 | 1 | DOD |
| 8 | SD | SD | – | – | 510 | 3 | SD |
| 9 | PD | – | 5 | Cerebral metastasis | 158 | 0 | DOD |
| 10 | SD | PD | 6a | Soft tissue mass | 189 | 1 | DOD |
aPatient 10 relapsed after the sixth month of evaluation
PD progressive disease; CR complete response; PR partial response; SD stable disease; DOD died of the disease